A range of inflammatory conditions is associated with pathologically high levels of circulating chromogranin A (CgA). This prohormone belongs to the family of uniquely acidic proteins co-stored and co-secreted with other hormones and peptides from the diffuse neuroendocrine system. Two highly conserved, CgA-derived peptides, vasostatin-I and catestatin, have been implicated as modulators of a wide range of cells and tissues, including those of the cardiovascular system. This review focuses on links between elevated circulating CgA and cardiovascular dysfunctions in inflammatory conditions in relation to potential beneficial effects of vasostatin-I and catestatin. Characteristic membrane-penetrating properties have been assigned to both peptides, and pertussis toxin sensitivity is shared by a number of their responses, notably in the vascular and cardiac endothelium. Pertussis toxin-sensitive, receptor-independent activation via heterotrimeric G proteins and Gai/o subunits will be discussed as possible mechanisms for inhibitory effects of vasostatin-I and catestatin on vascular and cardiac responses. The accumulated evidence provides convincing support for vasostatin-I and catestatin as regulatory peptides for the cardiovascular system, converging on alleviation of significant dysfunctions as part of several inflammatory conditions.
Introduction
Internal sensors for plasma glucose, calcium, oxygen, and other metabolically important regulators converge on elements of the diffuse neuroendocrine system, regulating storage and release of chromogranin A (CgA) with hormones such as catecholamines (CA), insulin, and parathyroid hormone (PTH). 1, 2 CgA is an established member of the granin family of genetically distinct and uniquely acidic proteins, ubiquitously stored in secretory cells of the nervous and endocrine system 3, 4 and exocytotically co-released with CA from the adrenal medulla. 5 The numerous pairs of basic amino acids are sites for posttranslational processing, 3 and the phylogenetically highly conserved N-and C-termini domains 2 are consistent with a role for the cargo protein CgA as a prohormone for shorter fragments with regulatory properties. 6 The prohormone concept implies that intact CgA is processed into smaller biologically active peptides, acting locally and/or at some distance from sites of release. Evidence in favour of functional roles for several CgA-derived peptides ( Figure 1 ) is steadily on the rise. 2 Notably pancreastatin 7 and vasostatin-I (VS-I, CgA 1 -76 ) 8 have been proposed as homeostatic regulators of plasma glucose and calcium, respectively. 9 Another CgA product, catestatin (Cts, bCgA 344 -364, hCgA 352 -372) ) is postulated to play a role in peripheral 10, 11 and baroreceptor regulation of hypertension. 12, 13 CgA is well established as a conspicuous component in the peripheral circulation.
14 Also cells and tissues outside the neuroendocrine system have been demonstrated to produce and secrete CgA and CgA-derived peptides. For example, CgA is produced in myocardial cells, 15 -17 suggesting discharge of the prohormone and its processed products from the heart itself, presumably contributing to local modulation of cardiac responses. A vast number of reports on pathologically high levels of plasma CgA have accumulated since the first documentation of increased levels in patients with neuroendocrine tumours. 14 Accordingly, plasma CgA is by now a commonly used diagnostic and prognostic marker, not only for tumours of neuroendocrine origin, 18 but also for systemic diseases. These include renal and hepatic failure, cardiac arrest and essential hypertension, 19 and in inflammatory conditions such as heart failure, 20 rheumatoid arthritis (RA), 21, 22 systemic lupus erythematosis, 23 and arteritis. 24 The purpose of this review is to integrate the available data on the CgA-derived VS-I and Cts domains into a coherent picture of their potentials as cardiovascular modulators. Receptorindependent cell activation forms the basis for a common pathway for pertussis toxin (PTX)-sensitive responses to VS-I and Cts, lending support from their similarities in membrane penetrating properties 25 -30 with other cationic, amphipathic, or hydrophobic peptides implicated in self-defence and innate immunity.
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VS-I and Cts as modulators of significant tissue responses
Numerous reports point to the CgA-derived VS-I and Cts as modulators of a wide range of significant tissue responses ( Table 1) . Notably VS-I appears as the most versatile of these two highly conserved CgA domains, being involved in modulation of vasoconstriction, 8, 31, 32 plasma calcium, 33 endothelial integrity, 34 -36 and myocardial inotropy. 37 -41 Moreover, VS-I triggers microglial activation 42 and cell adhesion, 43 inhibits gastrointestinal motility 44 and affects the first line of defence against invading microorganisms. 45 As evident from Table 1 , also Cts emerges as a multifunctional peptide beyond the first reported autocrine inhibition of catecholamine release from the bovine adrenal medulla 10 and the most recent reports on baroreceptor activation. 12, 13 In addition, Cts targets also to a range of microorganisms, 46 ,47 mast cells, 48, 49 endocardial (EEC) 50 and coronary endothelia (CEC), 51 and neutrophils (PMNs).
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A novel role for plasma CgA during inflammatory provocations
The release of CgA from the diffuse neuroendocrine system derives from a wide range of environmental and intrinsic stimuli, ultimately elevating the concentrations of the unprocessed and processed prohormone in the extracellular space and circulation. While the role of CA and primary peptide hormones in Figure 1 Schematic illustration of the localization of the main biologically active peptides derived from CgA (hCgA 1 -439 homeostatic regulations is undisputable, this is not so for the co-released cargo, e.g. CgA. A function for CgA in its own right and as a prohormone for peptides with regulatory properties has up to now remained uncertain. A recent report demonstrates a significant link between pathologically high plasma levels of CgA in patients with RA and a protective effect via VS-I against TNFa-induced impairment of EC integrity. 22 In the RA patients, the plasma CgA levels were .five-fold higher than normal and in a group of severe manifestations .25-fold above the normal level of 1 nM. Importantly, RA sera but not control sera, inhibited the TNFa-induced expression of cytoskeletal components (ICAM-I) in cultured microvascular EC, an effect that was blocked by antisera to the N-and C-termini of human CgA and mimicked by recombinant CgA and VS-I. 22 The role of EC dysfunction as a marker for future cardiovascular events is well established in patients with essential hypertension 54 and in the progression of atherosclerotic lesions. 55 Thus, the alleviating effect of high plasma CgA on EC dysfunction 22 provides the first support for a beneficial role for high plasma CgA in an inflammatory disease such as RA with its characteristic vascular, extra-articular impairments. Moreover, the protective effect of the RA sera via VS-I corroborates a previous report in which the natural human CgA, VS-I and the synthetic peptide CgA 7 -57 mimicked the inhibitory effect of tumour produced CgA on the TNFa-induced leakage of marker dye through the venous EC in mice. 34 In these experiments concentrations of plasma CgA above 7 nM were required, indicating relevance notably for the pathologically high plasma CgA reported not only for neuroendocrine tumours 14, 18, 32 but also for chronic heart failure, 20,56 rheumatoid diseases, 21 -24 and hypertension. 19 The regulatory properties inherent in the vascular and cardiac endothelium are significantly different despite the continuity of the monolayer of cells that lines the entire cardiovascular system, differing in origin 57 and involvement in cytoprotection and immunological and inflammatory processes. 58 While an intact EEC helps to modulate left-ventricular function, 59 abnormalities in NO generation have been demonstrated in various cardiac pathologic states, especially atherosclerotic vascular disease, congestive heart failure, and essential hypertension. 60 Of note, a profound degree of EC dysfunction results from cardiac reperfusion after an ischaemic insult, with loss of NO and up-regulation of adhesion molecules. 61, 62 Hence, any dysfunction in CEC and EEC becomes a critical factor in pathological conditions such as essential hypertension, cardiac myopathies, and cardiac failure, 59 i.e.
when plasma CgA is reportedly higher than normal. 19, 20, 56 In this context, the protection against disruption of EC continuity in response to inflammatory agents by VS-I 34, 35 and the protective effects of preconditioning with VS-I against myocardial infarction during cardiac reperfusion 41 together point to a significant role of the VS-I domain in CgA in alleviation of EC-derived cardiovascular dysfunctions. A beneficial role for the Cts domain of CgA has been related to the suppression of CA release from the sympathoadrenal elements and modulation of the baroreceptor responses in essential hypertension. 10 -13 It has been difficult to coin the genes responsible for development of the trait 63 and in hypertension the plasma level of
CgA is elevated in some 19 but not in all groups. 64 However, in patients with established hypertension and those with a genetic risk for this disease, plasma level of Cts is diminished despite the elevated levels of CgA, suggesting a deficiency of Cts caused by limited processing of the prohormone. 65 Intriguingly, whether the limited processing also affected the release of the VS-I domain was not mentioned. Of note, from re-sequencing of the human CgA gene, three variants of the natural Cts have been identified, 12 differing in potencies for inhibition of CA secretion and in degree of processing by the endoproteolytic enzyme plasmin. 65 It has been argued that the dominating, normal Cts is the least efficiently processed variant. When coupled with a strong association with ethnicity and sex, these three variants might contribute to the differential prevalence of essential hypertension across ethnic groups. 12, 65 In contrast, natural variants of the VS-I domain in the human CgA gene have so far not been reported. Paradoxically, hypertension is also a characteristic symptom in the CgA-null mice. 66 The consequences of deficiency in CgA have been analysed by two groups, 66,67 agreeing on elevated excretion of CA although diverging with respect to adrenomedullary morphology and endocrine functions. Of note, the elevated blood pressure could be rescued by insertion of the human CgA gene in the CgA null mice, consistent with a hypotensive effect of CgA. 66 Injection of exogenous Cts also caused hypotension in the CgA-null mice, 66 however without clarifying whether this effect was secondary to a histamine release from mast cells, as in the rat. 48 In view of EC dysfunction being an integral factor in hypertension, 54, 55 and the protective effects of the VS-domain on EC integrity when exposed to inflammatory cytokines, one would expect that a deficiency in VS-I would also have significant bearings on the blood pressure in the CgA-null mice. Thus, although the human CgA gene is a candidate for intermediate phenotypes of Cts that may contribute to hypertension in a race and sex-specific pattern, the causal relationship between CgA and essential hypertension may be more complex than so far envisaged 12, 13, 66 from the hypotensive effects of Cts alone.
VS-I, Cts, and PTX-sensitive, receptor-independent signalling
The signalling pathways involved in the cardiovascular responses to VS-I and Cts are only fragmentary at present. Despite four decades since the exocytotic release of CgA was first established, 5 classical surface receptors for the multitude of effects presently assigned to VS-I and to the effects of Cts outside the central and peripheral sympathoadrenal system ( However, this receptor cannot account for the histamine-releasing, hypotensive effect of Cts in the rat, 48 nor for the activation of NO production in frog and rat hearts 50, 51 or the stimulation of protein release from PMNs. 52, 53 Intriguingly, a common feature of many of Cardiovascular actions of VS-I and Cts the responses to VS-I and Cts is their sensitivity to PTX. This applies to VS-I in cultured bovine pulmonary and CEC, 35 in EEC of isolated fish hearts, 38 in CEC of rat hearts, 39 -41 and in bovine coronary resistance arteries, 31 and to Cts in the rat mast cells 49 and rat CEC. 51 It seems likely that Cts may elicit its PTX-sensitive, mastoparan-and substance P (SP)-like activation of histamine release in the rat mast cells 49 by a mechanism analogous to the receptor-independent activation of a PTX-sensitive Gai/o subunit 68 already established for the cationic and hydrophobic mastoparan and SP. 69, 70 PTX, the Bordetella pertussis toxin, is commonly used to identify G protein-regulated signalling pathways coupled to Gai/o subunits. The carboxyl end of the Gai/o subunit and the cationic cluster in the third intracellular loop of the G-protein coupled receptors (GPCR) is crucial for the activation, leading to a GTP-dependent dissociation of Gai/o from Gbg and subsequent signalling. PTX specifically catalyses ADP-ribosylation of a cysteine residue at the C-terminal of Gai/o subunits, thereby inactivating the subunit and preventing the GDP-dependent dissociation and further signalling. 68 Direct effects of PTX on cellular functions in the absence of GPCR have been noted in numerous cell systems. 69 -73 In the case of the PTX-sensitive stimulation of histamine release by cationic peptides from rat mast cells, the cationic peptide residues may replace the cationic cluster of the GPCR molecule, eliciting the secretory response in a receptor-mimetic manner, i.e. independent of GPCR. 69, 70 Importantly, the dissociated GTP-Gai/o may interact with effectors with manifold higher affinities than in their GDP-bound states and may, in addition to the free bg dimers, target to a multitude of distinct and cell-specific targets. For instance, in pulmonary EC the Gai/o subunit exerts a tonic inhibition on the phosphorylation of p38MAPK 71 while in the rat mast cells this subunit exerts a fast stimulation of histamine release. 69, 70 In turn, the free bg dimers are potent activators of a wide range of other signalling pathways in cell-specific manners, such as the inward rectifying K þ channels (GIRKs) in cardiac cells 74 and the slow release of arachidonic acid derivatives from rat mast cells. 75 Lipid -protein interactions are also crucial for the function of G-proteins, being able to translocate from membrane to cytosol. 76 A contribution of phospholipids and protein -lipid interactions to signalling is therefore also to be anticipated.
Cts and the mastoparan-like PTX-sensitive activation of histamine release from rat mast cells
The PTX-sensitive, mastoparan-like effect of the biologically active domain of Cts (cateslytin, bCgA 344 -358 ) on the rat mast cells initiated our hypothesis 49 of a receptor-mimetic effect analogous to that postulated for mastoparan and SP, 69, 70 as illustrated in Figure 2 . Nicotinic receptors undergo desensitization upon prolonged or repeated exposure to agonists. Intriguingly, Cts and the neuropeptide SP are more potent as inhibitors of nicotinic desensitization than of the nicotine-evoked secretion of CA in PC 12 cells. 11 However, no effect of PTX was obtained on Cts inhibition of the nicotine-induced release of noradrenaline in these cells, 10 nor is there any report on PTX sensitivity for the Cts and SP-induced desensitization of the nicotinic acetylcholine receptor. 11 Hence, the non-competitive inhibition and desensitization of the nicotinic receptor by Cts and SP appears distinct from the PTX sensitive, nicotine-induced CA release from chromaffin cells and the PTX potentiation of the calcium-evoked CA release from permeabilized cells. 77 The latter reportedly involves two distinct heterotrimeric G-proteins from the Gai/o family acting in series in the exocytotic pathway in chromaffin cells.
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Several PTX-sensitive signalling pathways have been identified, some only for VS-I, 26, 31 and others common to both VS-I and Cts, 40, 51 seemingly converging on protection against excessive stimulation of the respective cardiovascular elements. Moreover, the accumulated evidence supports the concept that VS-I may protect the mammalian heart against inotropic stimuli by activating PTX-sensitive NO-signalling cascades originating from EEC or CEC under normal 38 -40 and ischaemic conditions, respectively.
41
PTX-sensitive effects of Cts have so far been limited to the rat, stimulating release not only of histamine from mast cells 49 but also of NO from CEC. 51 Both VS-I and Cts may adopt amphipathic secondary structures in membrane-mimetic environments, 25 -30 consistent with passive penetration through microbial membranes. 25, 45, 46 Accordingly, our hypothesis of receptor-mimetic effects by membrane interaction due to the amphipathic property of the Cts peptide ( Figure 2 ) may be extended to the PTX-sensitive becomes translocated into the mast cell membrane containing the heterotrimeric G-protein so that the cationic charges on the active site of Cts may interact with the negative charges at the C-terminal of the Gai-subunit. 69, 70 By ADP-ribosylation of a cysteine residue of the carboxyl end of the Gai-subunit pertussis toxin (PTX) may inhibit this interaction. 68 Like mastoparan, the Cts interaction with the Gai-subunit may directly trigger the fast release of histamine while the release of the dissociated Gbg dimer may activate the slow release of arachidonic acid metabolites. 72, 75 responses to VS-I in the vascular EC ( Figure 3 ) and to VS-I and Cts in the CEC/EEC of the heart (Figure 4 ).
VS-I protects against PTX activation of p38MAPK in pulmonary and coronary arterial EC
A barrier-protective Gai/o subunit is postulated to regulate a tonic suppression of p38MAPK phosphorylation in bovine pulmonary arterial EC ( Figure 3A) . 71 PTX inactivation of the Gai/o subunit would thus lead to an increase in p38MAKP phopshorylation ( Figure 3B ) and subsequently to rearrangements of the actin cytoskeletal rearrangements that are essential for the characteristic disruptive effect of PTX on endothelial barrier dysfunction. 35 Antibodies to the cationic CgA 53 -57 epitope in the third amphipathic helix of VS-1 2, 76 has been shown to block the inhibitory effects of VS-1 on the TNFa -induced gap formations in EC. 34, 35 Not only the TNFa but also the PTX-induced gap formations could be blocked in the presence of VS-I or the specific inhibitor SB 203580 of p38MAPK. 35 Indeed, this PTX-sensitive inhibition of VS-1 on p38MAPK phosphorylation provided a clue to this puzzle. As illustrated in Figure 3C , a VS-I-induced interference with the PTX-sensitive site on the Gai/o subunit, involving the cationic epitope CgA 53 -57 , would prevent PTX inactivation of the Gai-subunit ( Figure 3B ) and thereby protect the tonic inhibition of the enzyme 71 ( Figure 3C as in 3A).
Negative myocardial inotropy, VS-I, Cts, and PTX-sensitive NO production
VS-1 and a range of VS-I-derived peptides containing the disulfide-bridged loop exert a potent negative inotropy under basal and b-adrenergic stimulation. 79, 80 Two CEC pathways have been demonstrated in the Langendorff perfused rat heart, one sensitive to PTX and signalling through NO-cGMP-PKG, 40, 41 and another signalling through adenosine (A1) and PKC. 41 Unlike VS-1, 39 -41,74 VS-I counteracted the ISO-mediated positive inotropism in a CEC-dependent manner, serving as non-competitive inhibitor of the b-adrenergic receptor on the cardiomyocyte (CM). Also catestatin (Cts) exerted a negative myocardial inotropy that was abolished by pre-treatment with inhibitors of eNOS, cGMP, or the CEC-located ETB receptor. 51 Cts increased heart rate and coronary pressure, 51 suggesting peptide specific differences in coupling to these two responses in the rat heart. On the other hand, Cts like VS-1 have been shown to non-competitively inhibit the b-adrenoceptor activation of the cardiomyocyte (CM), 39, 40, 50, 51 presumably mediated by the relaxing effect of the CEC-derived NO-release mediated by Akt/ PKB signalling to eNOS. 51 In addition, a non-competitive inhibition of the ET-1 receptor has also been assigned to Cts in CM. 51 A model summarizing these receptor-independent modulations is presented in Figure 4 . It is not yet established if these effects of VS-I and Cts are additive or competitive; in the first case possibly involving peptidespecific Gai/o subunits or in the second case by targeting to a common Gai/o subunit.
A suppressive effect of PTX on the CgA 1 -40 induced vasodilatation at moderately elevated extracellular [K þ ] has been reported in the EC-denuded, pressure-activated bovine coronary resistance artery. 31 Inward rectifying G-protein coupled K þ channels (GIRKs) are in general regulated by hormones and neurotransmitter, leading to a dissociation of Gai/o and Gbg subunits and hyperpolarization by the Gbg -activated channel. 81 However, GIRKs, primarily located in neurons and the heart, 74 have previously not been associated with vasodilatation in arterial VSMC. 82 In the absence of classical surface receptors heterotrimetic G proteins may also be regulated by additional accessory proteins (AGS). 83, 84 Intriguingly the different AGS proteins are postulated to function as guanine nucleotide exchange factors or guanine nucleotide dissociation inhibitors and may also influence subunit interactions by interacting with Gbg. For example, a 72 kDa rat AGS3 binds to the Gai of the heterotrimeric G protein and release the Gbg dimer for channel activation in the absence of a classical surface receptor. 85 Analogously, the specific VS-I-and 
Conclusion and perspectives
The accumulated evidence provides convincing support for VS-I and Cts as regulatory peptides for the cardiovascular system, converging on alleviation of significant dysfunctions as part of several inflammatory conditions. A novel link between elevated circulating CgA and cardiovascular dysfunctions has been discussed in relation to potential beneficial effects of these two highly conserved CgAderived peptides. In want of classical surface receptors for either peptide outside the central and peripheral sympathoadrenal system, three different patterns of receptor-independent activations via heterotrimeric G proteins and Gai/o subunits have been proposed on the basis of their reported PTX-sensitive responses.
Taken together, VS-I emerges as the most versatile of the CgAderived peptides, protecting the structural integrity of EC ( Figure 3 ) and counteracting inotropic activation of the vertebrate myocardium via activation of NO production in EEC/CEC (Figure 4) . In addition, VS-I may possibly also contribute to coronary vasodilatation via opening of GIRK channels in the VSMC via a PTX-sensitive, receptor-independent pathway. Multifunctional actions are also evident for Cts, more recently added to the list of CgA-derived modulators. This peptide acts not only via the baroreceptor and sympathoadrenal systems but also via PTX-sensitive, receptorindependent activations in mast cells (Figure 2 ) and the vertebrate heart ( Figure 4) .
Intriguingly, a functional role for the stable background of circulating CgA under normal conditions has yet to be substantiated. On the basis of the beneficial effects of the pathologically high CgA in plasma as presently discussed, it seems plausible that the normal levels of circulating CgA via its VS-I and Cts domains may provide a homeostatic buffer function against wear and tear of the cardiovascular elements before onset of disease, e.g. during periods of excessive activation from a wide range of environmental and intrinsic stimuli. 86 
